Breast cancer

• zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra … Recruiting
  2023-509598-22-01 6 2025-05-13 "Oncology - Breast cancer"
• SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient … Recruiting
  2024-516173-76-01 5 2025-04-22 "HER2-positive or HER2-low (incl. ultra-low) early breast can"
• A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors Recruiting
  2024-512019-36-00 1 2025-04-09 "Adrenocortical carcinoma"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• A study to learn more about how well treatment with sevabertinib (BAY2927088) tablets works and how safe it is in participants who have a so … Recruiting
  2024-517419-62-00 4 2025-02-28 "HER2 mutation"
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 "Recurrent or Metastatic Solid Tumors (endometrial cancer (EC"
• An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting
  2024-512161-14-00 3 2025-01-14 "Breast Cancer"
• Role of an hormonal vaginal therapy, the prasterone pessary, in the improvement of the vaginal/vulvar/urinary symptoms in menopausal women w … Recruiting
  2023-506211-18-00 5 2025-01-09 "Postmenopausal women with previous breast cancer or current"
• Permanence of Indocyanine Green in axillary lymph nodes three weeks after subdermal injection in patients with Breast Carcinoma and metastat … Recruiting
  2024-513163-57-00 4 2024-12-20 "Breast Cancer"
• Iodine Contrasts Effectiveness and Safety in Contrast Enhanced Mammography and breast magnetic resonance imaging. Recruiting
  2023-507644-37-00 5 2024-12-13
• A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys … Recruiting
  2023-508960-31-00 5 2024-12-03 "Metastatic HER2-positive breast cancer"
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 "Triple negative breast cancer"
• The RED FLASH study Recruiting
  2023-507847-13-00 5 2024-08-09
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 "Locally Advanced or Metastatic Solid Tumors Harboring a TP53"
• A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting
  2022-501725-21-00 1 2024-04-12 "Neuroblastoma"
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 "breast cancer"
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 "HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastati"
• Study of AZD9574 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies Recruiting
  2023-504984-17-00 7 2022-10-05 "Module 3: advanced/relapsed HER2-negative breast, ovarian, p"
• HIsTological and CLinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. (HITCLIF) Recruiting
  2023-504943-15-00 4 2022-08-19 "Cancer(colon cancer stage II-III, rectal cancer, and breast "
• NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment … Recruiting
  2023-510093-13-00 4 2022-05-11 "Patients with hormone receptor positive HER2 negative breast"
• EXTENSION STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLAXOSMITHKLINE/TESARO-SPONSORED NIRAPARIB STUDY AND ARE JUDGED BY THE INVESTIGATOR … Recruiting
  2023-506618-29-00 4 2021-09-22 "Advanced ovarian, breast, or prostate cancer"
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 "BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian can"
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz … Recruiting
  2023-508094-88-00 5 2021-02-08 "breast cancer"
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors Recruiting
  2023-508469-34-00 1 2020-10-14 "Esophageal cancer"

Showing 25–48 of 77 trials